Scott Coiante
Director of Finance/CFO presso AGILE THERAPEUTICS, INC.
Patrimonio netto: 51 606 $ in data 29/02/2024
Profilo
Presently, Scott M.
Coiante holds the position of Chief Financial Officer, Treasurer & Senior VP for Agile Therapeutics, Inc.
In the past he was CFO, Principal Accounting Officer & Senior VP at Agile Therapeutics, Inc., Chief Financial Officer, Secretary & Senior VP at Aprea Therapeutics, Inc. and Chief Financial Officer & Senior Vice President for Aprea Therapeutics AB (a subsidiary of Aprea Therapeutics, Inc.), Secretary at Aprea Therapeutics, Inc. and Chief Financial Officer & Senior Vice President for Aprea Therapeutics AB (a subsidiary of Aprea Therapeutics, Inc.), Treasurer, Chief Accounting Officer & VP-Finance at Medarex, Inc., Head-Financial Reporting at Ernst & Young LLP and Member of New Jersey Technology Council.
Scott M.
Coiante received an undergraduate degree from Villanova University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
APREA THERAPEUTICS, INC.
0.11% | 26/06/2023 | 4 213 ( 0.11% ) | 35 642 $ | 29/02/2024 |
AGILE THERAPEUTICS, INC.
0.68% | 03/10/2023 | 20 080 ( 0.68% ) | 15 964 $ | 29/02/2024 |
Posizioni attive di Scott Coiante
Società | Posizione | Inizio |
---|---|---|
AGILE THERAPEUTICS, INC. | Director of Finance/CFO | 16/08/2023 |
Precedenti posizioni note di Scott Coiante
Società | Posizione | Fine |
---|---|---|
APREA THERAPEUTICS, INC. | Director of Finance/CFO | 30/01/2023 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Director of Finance/CFO | 01/01/2023 |
AGILE THERAPEUTICS, INC. | Director of Finance/CFO | 05/08/2019 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Director of Finance/CFO | 01/01/2005 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formazione di Scott Coiante
Villanova University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
AGILE THERAPEUTICS, INC. | Health Technology |
APREA THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
New Jersey Technology Council
New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services New Jersey Technology Council provides business development, education and advocacy services. It serves communications, e-business, multimedia, consumer technologies, manufacturing, engineering and energy sectors. The company was founded in 1996 and is headquartered in New Brunswick, NJ. | Commercial Services |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |